Zheng Quan Shi Bao Wang·2025-11-10 01:17Core Insights - The company, Real Bio, has submitted an application to list on the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as its exclusive sponsor [1] - Real Bio focuses on the development, manufacturing, and commercialization of innovative drugs targeting viral infections, tumors, and cardiovascular diseases [1] Product Pipeline - The core product, Azvudine, is a class 1 innovative drug with a unique dual mechanism of action, approved conditionally in China in July 2021, and is the only oral nucleoside HIV treatment drug with dual targets globally [1] - Azvudine has shown significant potential in oncology by inhibiting tumor cell DNA synthesis and modulating the immune system, currently being advanced for blood cancers and solid tumors [1] - Other innovative candidates include: - CL-197: An oral HIV candidate with a long half-life of over 168 hours, aimed to be developed as the first all-oral, weekly HIV combination tablet [2] - Duoxitini: A third-generation EGFR-TKI candidate for non-small cell lung cancer (NSCLC) showing similar efficacy to Osimertinib but with better safety [2] - ZSSW-136: A novel TOPO1 inhibitor that demonstrates unique advantages in overcoming Irinotecan resistance, suitable as a new effective payload for ADCs [2] Fundraising Purpose - The funds raised will primarily accelerate the development and commercialization of Azvudine for HIV, blood cancers, and solid tumors, as well as support the development of CL-197 and Duoxitini [2] - Additional funding will support other drug pipelines, combination therapies, platform development, and general corporate purposes [2]